MarketCap
Prelude Therapeutics Incorporated PRLD
€ 3.43
0.53%
Facebook
X
Telegram
Prelude Therapeutics Incorporated Langfristiger Schuldenstrom | PRLD
Langfristiger Schuldenstrom Jährlich Prelude Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.74 M | 2.49 M | 1.48 M | 1.83 M | 1.74 M | - | - | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.74 M | 1.48 M | 2.06 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
2.91 M | $ 4.2 | -0.36 % | $ 651 M |  USA |
 |
AbbVie
ABBV
|
194 M | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Achieve Life Sciences
ACHV
|
61 K | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
6.99 M | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
83.5 K | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
202 M | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
4.71 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
1.59 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
19.1 M | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
135 M | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
234 K | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
2.66 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
14.3 M | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
2 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
380 K | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
234 K | $ 1.49 | -1.97 % | $ 3.67 B |  Israel |
 |
Sage Therapeutics
SAGE
|
1.32 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
816 K | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
500 K | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
21.8 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
6.37 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
222 M | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
226 K | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
521 K | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
6.49 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
263 K | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
3.83 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
194 K | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
11 K | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
15 K | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
17 M | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
814 K | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Kiromic BioPharma
KRBP
|
685 K | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
20.5 M | $ 38.41 | 1.67 % | $ 648 M | USA |
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
853 K | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
234 K | - | -23.04 % | $ 26.6 M | USA |
 |
Tyme Technologies
TYME
|
37.3 K | - | 8.07 % | $ 54 M | USA |
 |
Verona Pharma plc
VRNA
|
1.12 M | - | - | $ 69.7 B | Britain |